170 related articles for article (PubMed ID: 20604836)
1. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts.
Akiyama T; Dass CR; Shinoda Y; Kawano H; Tanaka S; Choong PF
J Pharm Pharmacol; 2010 Apr; 62(4):470-6. PubMed ID: 20604836
[TBL] [Abstract][Full Text] [Related]
2. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
3. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
4. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells.
Li Z; Li C; Zhou Y; Chen W; Luo G; Zhang Z; Wang H; Zhang Y; Xu D; Sheng P
Am J Physiol Endocrinol Metab; 2016 Mar; 310(5):E355-66. PubMed ID: 26670486
[TBL] [Abstract][Full Text] [Related]
6. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo.
Ishizuka H; García-Palacios V; Lu G; Subler MA; Zhang H; Boykin CS; Choi SJ; Zhao L; Patrene K; Galson DL; Blair HC; Hadi TM; Windle JJ; Kurihara N; Roodman GD
J Bone Miner Res; 2011 Jan; 26(1):169-81. PubMed ID: 20683884
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
9. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
11. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
12. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
14. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
[TBL] [Abstract][Full Text] [Related]
17. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
Suzuki T; Suda N; Ohyama K
J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Miller RE; Branstetter D; Armstrong A; Kennedy B; Jones J; Cowan L; Bussiere J; Dougall WC
J Immunol; 2007 Jul; 179(1):266-74. PubMed ID: 17579046
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction.
Lee SK; Park KK; Park JH; Lim SS; Chung WY
Phytother Res; 2013 Dec; 27(12):1776-83. PubMed ID: 23401151
[TBL] [Abstract][Full Text] [Related]
20. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
